BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that 74 percent of surveyed U.S. neurologists indicate that they will prescribe Biogen Idec’s oral immunomodulator BG-12 for the treatment of relapsing-remitting multiple sclerosis (MS), and 32 percent expect to prescribe the drug to patients with clinically isolated syndrome—the highest levels of support expressed by surveyed neurologists who evaluated four late-stage emerging therapies profiled in the report. These findings likely reflect neurologists’ positive perception of BG-12’s clinical profile, which combines strong efficacy, good tolerability, convenient formulation, unique mechanism of action and a favorable safety profile to date.
